We then evaluated the efficacy of the drug combinations in twodiagnosis-stage FLT3-ITD-mutated AML patient samples (Fig. 5A), with blast cell percentage ≥ 58% and anFLT3-ITD variant allele frequency ≥ 70% (Table S1). Here, FLT3 is linked to acute myeloid leukemia.